Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 17.57%.

  • Puma Biotechnology's EBITDA Margin fell 98400.0% to 17.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.83%, marking a year-over-year increase of 25300.0%. This contributed to the annual value of 13.44% for FY2024, which is 4200.0% down from last year.
  • Per Puma Biotechnology's latest filing, its EBITDA Margin stood at 17.57% for Q3 2025, which was down 98400.0% from 12.66% recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's EBITDA Margin ranged from a high of 27.41% in Q3 2024 and a low of 31.16% during Q2 2021
  • Moreover, its 5-year median value for EBITDA Margin was 8.96% (2023), whereas its average is 7.13%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -412600bps in 2021, then soared by 514200bps in 2022.
  • Quarter analysis of 5 years shows Puma Biotechnology's EBITDA Margin stood at 0.91% in 2021, then skyrocketed by 1358bps to 11.43% in 2022, then soared by 79bps to 20.5% in 2023, then grew by 10bps to 22.62% in 2024, then decreased by -22bps to 17.57% in 2025.
  • Its EBITDA Margin was 17.57% in Q3 2025, compared to 12.66% in Q2 2025 and 8.66% in Q1 2025.